Inventiva Appoints Jason Campagna as New R&D President and CMO

Inventiva has appointed Jason Campagna as its new president of R&D and CMO, replacing Pierre Broqua, who transitioned to a consultancy role, and Michael Cooreman, who left the position. Campagna brings experience in the MASH domain and joins from Q32 Bio, where he served as CMO.

Inventiva, a clinical-stage biopharmaceutical company focused on oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), has appointed Jason Campagna as President of Research and Development (R&D) and Chief Medical Officer (CMO), replacing Pierre Broqua, who transitioned to a consultancy role, and Michael Cooreman, who left the position [1]. Campagna brings extensive experience in the MASH field, having previously served as CMO at Q32 Bio.

Campagna joins Inventiva from Q32 Bio, where he was CMO, and previously held the role of MASH Global Program Lead and CMO at Intercept Pharmaceuticals. He will succeed Pierre Broqua, who co-founded Inventiva and served as its Chief Scientific Officer, and Michael Cooreman, who served as CMO. Broqua will continue to support the team in a scientific consulting role, while Cooreman will pursue new opportunities.

In addition to Campagna, Inventiva has appointed Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. Zimmermann comes from Ipsen, where she successfully led a team that secured regulatory approvals for two liver disease drugs, including Iqirvo®, a dual PPARα/δ agonist for primary biliary cholangitis. Prior to Ipsen, she served as Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharma (also known as AstraZeneca Rare Disease).

These appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026. Campagna and Zimmermann will play pivotal roles in the company's plans for the readout of NATiV3 Phase 3 study next year and lanifibranor's potential regulatory approval and commercialization.

References:
[1] https://www.biospace.com/press-releases/inventiva-names-jason-campagna-as-president-of-r-d-and-chief-medical-officer-and-martine-zimmermann-as-executive-vice-president-of-regulatory-affairs-and-quality-assurance